Akebia (NASDAQ: AKBA) plans major increase in authorized common shares
Akebia Therapeutics is seeking shareholder approval to significantly increase its authorized common shares from 350 million to 500 million, and total capital stock from 375 million to 525 million, at its virtual 2026 annual meeting on June 17, 2026. This move aims to provide the company with greater flexibility for future financing, strategic deals, and equity incentives without requiring further charter amendments. Shareholders will also vote on director elections, executive compensation, its frequency, and the ratification of Ernst & Young LLP as the independent auditor.
JAN 7·Yahoo Finance▲
Akebia announces first patient dosed in Phase 2 trial of praliciguat
Akebia Therapeutics has announced that the first patient has been dosed in a Phase 2 clinical trial for praliciguat, a soluble guanylate cyclase (sGC) stimulator. This drug is being evaluated for the treatment of biopsy-confirmed FSGS, a rare kidney disease, with potential future applications for other rare podocytopathies. There are currently no approved treatments for FSGS, which impacts approximately 40,000 patients in the U.S., and praliciguat has shown no significant safety issues in previous Phase 1 and 2 studies.
NOV 13·Zacks Commentary→
Implied Volatility Surging for Akebia Therapeutics Stock Options
Investors need to pay close attention to AKBA stock based on the movements in the options market lately.
